Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BridgeBio Pharma, Inc.

< Previous 1 2 3 Next >
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Tickers BBIO
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.